The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Open accessAbstract
There is a critical need for safer and more convenient treatments for organ transplant rejection and autoimmune disorders such as rheumatoid arthritis. Janus tyrosine kinases (JAK1, JAK3) are expressed in lymphoid cells and are involved in the signaling of multiple cytokines important for various T cell functions. Blockade of the JAK1/JAK3-STAT pathway with a small molecule was anticipated to provide therapeutic immunosuppression/immunomodulation. The Pfizer compound library was screened against the catalytic domain of JAK3 resulting in the identification of a pyrrolopyrimidine-based series of inhibitors represented by CP-352,664 (2a). Synthetic analogues of 2a were screened against the JAK enzymes and evaluated in an IL-2 induced T cell blast proliferation assay. Select compounds were evaluated in rodent efficacy models of allograft rejection and destructive inflammatory arthritis. Optimization within this chemical series led to identification of CP-690,550 1, a potential first-in-class JAK inhibitor for treatment of autoimmune diseases and organ transplant rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Noguchi, M. (1993) · Cell · doi:10.1016/0092-8674(93)90167-o · Cited by 1,320
Janus kinases in immune cell signaling
Ghoreschi, K., Laurence, A., & O’Shea, J. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00754.x · Cited by 1,149
The World Intellectual Property Organization
(2012) · International Organizations in WTO Dispute Settlement · doi:10.1017/cbo9781139235969.011 · Cited by 884
Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID)
Macchi, P., Villa, A., Giliani, S., Sacco, M. G., Frattini, A., Porta, F., Ugazio, A. G., Johnston, J. A., Candotti, F., O'Sheai, J. J., et al. (1995) · Nature · doi:10.1038/377065a0 · Cited by 877
Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development
Russell, S. M., Tayebi, N., Nakajima, H., Riedy, M. C., Roberts, J. L., Aman, M. J., Migone, T.-S., Noguchi, M., Markert, M. L., Buckley, R. H., et al. (1995) · Science · doi:10.1126/science.270.5237.797 · Cited by 803
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
Changelian, P. S., Flanagan, M. E., Ball, D. J., Kent, C. R., Magnuson, K. S., Martin, W. H., Rizzuti, B. J., Sawyer, P. S., Perry, B. D., Brissette, W. H., et al. (2003) · Science · doi:10.1126/science.1087061 · Cited by 607
Self-citationKremer, J. M., Bloom, B. J., Breedveld, F. C., Coombs, J. H., Fletcher, M. P., Gruben, D., Krishnaswami, S., Burgos‐Vargas, R., Wilkinson, B., Zerbini, C. A. F., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24567 · Cited by 546
Meyer, D. M., Jesson, M. I., Li, X., Elrick, M. M., Funckes-Shippy, C. L., Warner, J. D., Gross, C. J., Dowty, M. E., Ramaiah, S. K., Hirsch, J. L., et al. (2010) · Journal of Inflammation · doi:10.1186/1476-9255-7-41 · Cited by 461
Obach, R. S. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)39043-3 · Cited by 397
Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J., & Lucet, I. S. (2009) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.01.041 · Cited by 270
Selectivity and therapeutic inhibition of kinases: to be or not to be?
Ghoreschi, K., Laurence, A., & O'Shea, J. J. (2009) · Nature Immunology · doi:10.1038/ni.1701 · Cited by 241
Chrencik, J. E., Patny, A., Leung, I. K., Korniski, B., Emmons, T. L., Hall, T., Weinberg, R. A., Gormley, J. A., Williams, J. M., Day, J. E., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.05.020 · Cited by 227
Dalvie, D., Obach, R. S., Kang, P., Prakash, C., Loi, C.-M., Hurst, S., Nedderman, A., Goulet, L., Smith, E., Bu, H.-Z., et al. (2009) · Chemical Research in Toxicology · doi:10.1021/tx8004357 · Cited by 188
The Novel JAK-3 Inhibitor CP-690550 Is a Potent Immunosuppressive Agent in Various Murine Models
Kudlacz, E. M., Perry, B. D., Sawyer, P. S., Conklyn, M. J., McCurdy, S. P., Brissette, W. H., and, M. F., & Changelian, P. S. (2003) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00281.x · Cited by 154
Self-citationBusque, S., Leventhal, J. R., Brennan, D. C., Steinberg, S., Klintmalm, G. B. G., Shah, T., Mulgaonkar, S., Bromberg, J. S., Vincenti, F., Hariharan, S., et al. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02720.x · Cited by 154
Immunosuppressive agents in organ transplantation: past, present, and future.
Hong, J. C., & Kahan, B. D. (2000) · PubMed · Cited by 145
Chen, M., Cheng, A., Chen, Y.-Q., Hymel, A., Hanson, E. P., Kimmel, L. H., Minami, Y., Taniguchi, T., Changelian, P. S., & O’Shea, J. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6910 · Cited by 144
Self-citationCartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis
Milici, A. J., Kudlacz, E. M., Audoly, L., Zwillich, S. H., & Changelian, P. S. (2008) · Arthritis Research & Therapy · doi:10.1186/ar2365 · Cited by 142
Self-citationJak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs
Pesu, M., Candotti, F., Husa, M., Hofmann, S. R., Notarangelo, L. D., & O’Shea, J. J. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00220.x · Cited by 134
Jiang, J., Ghoreschi, K., Deflorian, F., Chen, Z. J., Perreira, M., Pesu, M., Smith, J. A., Nguyễn, Ð.-T., Liu, E. H., Leister, W., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm801142b · Cited by 131
Oakes, S. A., Candotti, F., Johnston, J. A., Chen, Y., RYAN, J., Taylor, N. N., Liu, X., Hennighausen, L. G., Notarangelo, L. D., Paul, W. E., et al. (1996) · Immunity · doi:10.1016/s1074-7613(00)80274-5 · Cited by 125
Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency
Johnston, J. A., Bacon, C. M., Riedy, M. C., & O’Shea, J. J. (1996) · Journal of Leukocyte Biology · doi:10.1002/jlb.60.4.441 · Cited by 109
Cytokines and their role in lymphoid development, differentiation and homeostasis
Hofmann, S. R., Ettinger, R., Zhou, Y., Gadina, M., Lipsky, P. E., Siegel, R. M., Candotti, F., & O’Shea, J. J. (2002) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/00130832-200212000-00004 · Cited by 103
van Gurp, E., Weimar, W. W., Gaston, R. S., Brennan, D. C., Mendez, R., Pirsch, J. D., Swan, S. K., Pescovitz, M. D., Ni, G., Wang, C., et al. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02307.x · Cited by 76
Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy
Rousvoal, G., Si, M., Lau, M., Zhang, S., Berry, G. J., Flores, M. G., Changelian, P. S., Reitz, B. A., & Borie, D. C. (2006) · Transplant International · doi:10.1111/j.1432-2277.2006.00387.x · Cited by 37
Self-citationKalgutkar, A. S. S., Hatch, H. L., Frederick, K. S., Hang, N. T. T., Choo, E. F., McClure, K. F., Taylor, T. J., Henne, K. R., Kuperman, A. V., Dombroski, M. A., et al. (2006) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.520 · Cited by 34
Disposition of CP-671, 305, a selective phosphodiesterase 4 inhibitor in preclinical species
Kalgutkar, A. S. S., Choo, E. F., Taylor, T. J., & Marfat, A. (2004) · Xenobiotica · doi:10.1080/00498250400005682 · Cited by 20
Chapter 12 Advances in the Discovery of Small Molecule JAK3 Inhibitors
Wrobleski, S. T., & Pitts, W. J. (2009) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(09)04412-1 · Cited by 19
Stock, P. G. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00115.x · Cited by 5
Cited by
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
van Vollenhoven, R. F., Fleischmann, R., Cohen, S., Lee, E. B., García Meijide, J. A., Wagner, S., Forejtova, S., Zwillich, S. H., Gruben, D., Koncz, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112072 · Cited by 945
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Vranic, I., Su, C., Rousell, S., & Niezychowski, W. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112168 · Cited by 800
The signal pathways and treatment of cytokine storm in COVID-19
Yang, L., Xie, X., Tu, Z., Fu, J., Xu, D., & Zhou, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00679-0 · Cited by 603
Metadata
- Authors
- Flanagan, M. E., Blumenkopf, T. A., Brissette, W. H., Brown, M. F., Casavant, J. M., Shang-Poa, C., Doty, J. L., Elliott, E. A., Fisher, M. B., Hines, M., Kent, C., Kudlacz, E. M., Lillie, B. M., Magnuson, K. S., McCurdy, S. P., Munchhof, M. J., Perry, B. D., Sawyer, P. S., Strelevitz, T. J., Subramanyam, C., Sun, J., Whipple, D. A., & Changelian, P. S.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2010-11-24
- Volume
- 53
- Issue
- 24
- Pages
- 8468-8484
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1995629248
- Cited by
- 334
- References
- 32
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.